Status:
UNKNOWN
Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Basal like breast carcinoma is a Her2, estrogen receptor (ER) progesterone receptor (PR) negative breast cancer. It is notable for the high level of epidermal growth factor receptor (EGFR) expression ...
Detailed Description
Basal like breast carcinoma is a Her2, ER PR negative breast cancer. It is notable for the high percentage of EGFR expression in this tumor subtype.Weekly taxol (paclitaxel) is widely used in breast c...
Eligibility Criteria
Inclusion
- Patients with metastatic breast carcinoma of the basal like subtype with available biopsy for analysis and ECOG PS of 2 or less
Exclusion
- Pregnancy
- BUN, blood creatinine, AST, ALT \> X3 of upper limits of normal
- More than previous 2 chemotherapy lines in the metastatic settings or the use of previous inhibitors of EGFR
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00353717
Start Date
November 1 2006
End Date
September 1 2009
Last Update
January 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Department Hadassah Ein Kerem POB 12000
Jerusalem, Israel, 91120